MedTrace Logo

AMAZ-02 Effect on Exercise ToLerance in Healthy, Overweight Middle Aged Subjects (ATLAS Trial)

NCT03464500 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-08-17

No results posted yet for this study

Summary

This is a Phase 2 randomized, double-blind, placebo-controlled study enrolling 90 healthy, overweight, middle aged subjects (30 placebo, 30 low dose and 30 high dose AMAZ-02 intervention), 40-65 years of age, who are otherwise healthy. AMAZ-02, a food derived ingredient, will be given as a daily oral dose for 4 months.

Conditions

  • Muscle Function, Mitochondrial Function
  • Overweight
  • Healthy Aging

Interventions

DIETARY_SUPPLEMENT

Mitopure 500mg

Mitopure containing softgels

DIETARY_SUPPLEMENT

Mitopure 1000mg

Mitopure containing softgels

DIETARY_SUPPLEMENT

Placebo

Placebo containing softgels

Sponsors & Collaborators

  • KGK Science Inc.

    collaborator INDUSTRY

  • Amazentis SA

    lead INDUSTRY

Principal Investigators

  • Mal Evans, PhD · KGK Science Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-06
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03464500 on ClinicalTrials.gov